In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?

Psychodynamic therapy isn’t outdated.
It’s evolving. Grounded in evidence.

You’ve just given a preliminary diagnosis of borderline personality disorder. Now what?

In the latest issue of TCPR, we give a lot of real estate to ADHD.
And for good reason. It’s a diagnosis that’s everywhere—expanding across age groups, personality types, and practice settings.

Busy clinicians don’t need more noise, they need clarity. That’s the idea behind the new Carlat Fact Sheet Web App: fast, searchable psychiatry you can actually use.